U.S government regulators are accusing some telehealth companies of deceptive, unethical business practices, including disclosing their customers’ health data, signing them up for hard-to-cancel subscriptions and bypassing real-time consultations with doctors. Here's what you need to know.

GRINDR TO BUY HIV-PREVENTION TELEHEALTH PROVIDER FREDDIE FOR $250M $GRND agreed to acquire Freddie parent PurposeMed for $190M in cash and $60M in stock, marking its first major acquisition. Freddie focuses on HIV-prevention telehealth, including access to PrEP, and will be combined with Grindr’s existing Woodwork telehealth business under a new Grindr Health offering. Grindr plans to focus on expanding Freddie in the U.S., where it sees roughly a $240M annual revenue opportunity based on 50,000 patients. The company says the deal should be immediately accretive to EBITDA, though margins could initially be pressured as it invests in growth. PurposeMed could also receive up to another $70M if it hits 2027 performance targets. The deal is expected to close in Q4. Source: WSJ

FDA CRACKS DOWN ON COMPOUNDED GLP-1s The FDA is warning telehealth firms and compounders over unapproved weight-loss drugs including semaglutide, tirzepatide and retatrutide. $HIMS The agency says retatrutide and cagrilintide cannot legally be used in compounding, and has already warned companies marketing unapproved retatrutide directly to consumers. As of May 31, the FDA had received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. The FDA is also flagging dosing errors, fraudulent labels, improper refrigeration during shipping and questionable foreign-made ingredients, while reiterating that compounded GLP-1s are not FDA-approved or reviewed for safety, effectiveness or quality before being marketed.

The Supreme Court allowed women to continue to access the abortion pill mifepristone through telehealth visits, imposing a pause on a May 1 decision from the 5th US Circuit Court of Appeals that abruptly required women to obtain the drug through in-person visits.